Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics

While gene therapy companies rejoice as the sector gains traction with approvals and a flurry of M&A activity, one player is feeling the heat.

Back in 2015, Voyager Therapeutics joined forces with Sanofi Genzyme in a deal worth up to $845 million ($100 million upfront + a potential $745 million in milestones) to co-develop gene therapies for severe central nervous system disorders.